The COVID-19 virus is putting a wrinkle in the agency's activities.
News & Analysis: Inovio Pharmaceuticals
Investors may want to think twice before buying this vaccine stock on the heels of the COVID-19 threat.
The biotech could start testing its coronavirus vaccine as early as this summer.
The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.
These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.
Gilead Sciences may be winning the race to develop the first coronavirus treatment.
The president declared the spreading coronavirus to be a public health emergency.
Shares got another boost from the ongoing coronavirus outbreak.
Two stocks fell, while one popped, as investors speculate over the potential financial impact from the Wuhan coronavirus outbreak. (Hint: it's unlikely to move the needle.)
Markets are starting the week off on a worried note, with major exchanges around the world reporting major losses.